Indication

ARPKD

1 clinical trial

1 product

Clinical trial

A Phase 3b Multicenter Open-label Trial of the Safety, Tolerability, and Efficacy of Tolvaptan in Infants and Children 28 Days to Less Than 18 Years of Age With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Status: Recruiting, Estimated PCD: 2026-04-27

Product